Steve joined TopiVert in 2011 as Chief Scientific Officer with the additional responsibility for managing day to day company operations as well as leading the development of the company’s technology and pipeline. He is an Executive Director of TopiVert. Steve has 18 years of experience working in all phases of drug discovery, from target identification through to Phase I clinical trials. He moved to TopiVert from his previous role as Senior Director of Drug Discovery at Almirall Pharma in Barcelona. Steve also held positions of increasing responsibility in Rhone-Poulenc Rorer and Aventis and was Vice President of Biology in the Respiratory CEDD in GlaxoSmithKline.  Steve trained as a pharmacologist, with degrees from Portsmouth Polytechnic (BSc) and University College London (PhD), and is an author on over 100 peer-reviewed publications. Steve joined TopiVert in 2011 as Chief Scientific Officer with the additional responsibility for managing day to day company operations as well as leading the development of the company’s technology and pipeline. He is an Executive Director of TopiVert. Steve has 18 years of experience working in all phases of drug discovery, from target identification through to Phase I clinical trials. He moved to TopiVert from his previous role as Senior Director of Drug Discovery at Almirall Pharma in Barcelona. Steve also held positions of increasing responsibility in Rhone-Poulenc Rorer and Aventis and was Vice President of Biology in the Respiratory CEDD in GlaxoSmithKline.  Steve trained as a pharmacologist, with degrees from Portsmouth Polytechnic (BSc) and University College London (PhD), and is an author on over 100 peer-reviewed publications.

fermentation